Member Info for BoNidel

As expected, there have been quite a few “Jump-Shippers” lately that have likely take a good profit and gone elsewhere.

Although I don’t begrudge anyone taking a few quid out, I cannot fathom how anyone could leave this with the covid trial results due imminently.

You’ve got to find something else & then potentially wait months or years to find a business that’s in such a pivotal moment such as TILS.

I have personally been invested earlier last year. I multi-bagged up to £3 & back down for accustem then to 80p where I bought again. I could easily take profits out of this, and as tempting as it was on Wednesday, I think it could be foolish to not ride out paper losses in anticipation of (what look to be) groundbreaking results.

Profit is not a dirty word by any means, but why sells a £20 note for a £10, just because you bought it for £5.

Please point out some other shares in a position like TILS with recent appointments, huge news due and £70m cash @ bank against a £350m Mcap.

Just my 2 pence worth.

Judging from recent RNS releases, the interview with Dr Shulabhai & the newest appointment, the results are likely to be positive.

The question we must ask is just how positive will they be, and indeed, will they warrant a roll out of perhaps the only nasally administered Antibody with potentially zero side effects to combat this virus.

The efficacy of the MAB appears to be positive judging from the short time to recover sense of smell as opposed to getting on for 4 weeks or so that non-treated carriers are experiencing.

Even if only effecting in 20/30% it would still be worth rolling out due to the low cost of nasal administration and low hospitalisation costs coupled with saving precious bed space.

The real question is how the market values...

“Tiziana Life Sciences (TLSA) is a client of RedChip Companies, Inc. TLSA agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2020, increasing to $15,000 monthly in August 2020, and $20,000 monthly in October 2020, for RedChip investor awareness services.”